ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

ClinicalTrials.gov ID: NCT03656926

Public ClinicalTrials.gov record NCT03656926. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Clinical Trial to Demonstrate Efficacy / Safety of Liposomal Cyclosporine A + Standard of Care (SoC) vs SoC Alone in Treating Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans in Patients Post Double Lung Transplant

Study identification

NCT ID
NCT03656926
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Zambon SpA
Industry
Enrollment
169 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 25, 2019
Primary completion
Mar 11, 2024
Completion
Mar 11, 2024
Last update posted
Feb 9, 2026

2019 – 2024

United States locations

U.S. sites
21
U.S. states
12
U.S. cities
19
Facility City State ZIP Site status
Banner Health Phoenix Arizona 85013
UCLA Medical Center Los Angeles California 90095
Stanford University Hospital Palo Alto California 94305
UC San Francisco San Francisco California 94143
University of Florida Medical Center Gainesville Florida 32608
Mayo Clinic Jacksonville Jacksonville Florida 32224
University of South Florida Tampa Florida 33606
Indiana University Indianapolis Indiana 46202
University of Kentucky Albert B. Chandler Hospital Lexington Kentucky 40508
University of Maryland Baltimore Maryland 21201
Johns Hopkins University Hospital Baltimore Maryland 21287
Washington University St Louis Missouri 63110
Columbia University Medical Center New York New York 10032
Duke University Medical Center Durham North Carolina 27110
Cleveland Clinic Cleveland Ohio 44195
Ohio State University Medical Center Columbus Ohio 43210
Temple University Hospital Philadelphia Pennsylvania 19140
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232
Baylor University Medical Center Dallas Texas 75246
Baylor College of Medicine Houston Texas 77030
Houston Methodist Hospital Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03656926, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 9, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03656926 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →